Literature DB >> 22649146

HER2 mutations in non-small-cell lung cancer can be continually targeted.

Ronan J Kelly, Corey A Carter, Giuseppe Giaccone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22649146     DOI： 10.1200/JCO.2012.43.4902

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

1.  Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.

Authors:  Xu Zhang; Khoa Dang Nguyen; Paul A Rudnick; Nitin Roper; Emily Kawaler; Tapan K Maity; Shivangi Awasthi; Shaojian Gao; Romi Biswas; Abhilash Venugopalan; Constance M Cultraro; David Fenyö; Udayan Guha
Journal:  Mol Cell Proteomics       Date:  2019-01-07       Impact factor: 5.911

2.  HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Authors:  Rathi N Pillai; Madhusmita Behera; Lynne D Berry; Mike R Rossi; Mark G Kris; Bruce E Johnson; Paul A Bunn; Suresh S Ramalingam; Fadlo R Khuri
Journal:  Cancer       Date:  2017-07-25       Impact factor: 6.860

3.  Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

Authors:  Wenhsiang Wen; Wangjuh Sting Chen; Nick Xiao; Ryan Bender; Anatole Ghazalpour; Zheng Tan; Jeffrey Swensen; Sherri Z Millis; Gargi Basu; Zoran Gatalica; Michael F Press
Journal:  J Mol Diagn       Date:  2015-09       Impact factor: 5.568

Review 4.  New targets in non-small cell lung cancer.

Authors:  Shirish M Gadgeel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

5.  Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Authors:  M G Kris; D R Camidge; G Giaccone; T Hida; B T Li; J O'Connell; I Taylor; H Zhang; M E Arcila; Z Goldberg; P A Jänne
Journal:  Ann Oncol       Date:  2015-04-21       Impact factor: 32.976

6.  HER2 expression status in diverse cancers: review of results from 37,992 patients.

Authors:  Min Yan; Maria Schwaederle; David Arguello; Sherri Z Millis; Zoran Gatalica; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2015-03       Impact factor: 9.264

7.  A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.

Authors:  Karen L Reckamp; Giuseppe Giaccone; D Ross Camidge; Shirish M Gadgeel; Fadlo R Khuri; Jeff A Engelman; Marianna Koczywas; Arun Rajan; Alicyn K Campbell; Diana Gernhardt; Ana Ruiz-Garcia; Stephen Letrent; Jane Liang; Ian Taylor; Joseph P O'Connell; Pasi A Jänne
Journal:  Cancer       Date:  2014-02-05       Impact factor: 6.860

8.  Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Authors:  Romi Biswas; Shaojian Gao; Constance M Cultraro; Tapan K Maity; Abhilash Venugopalan; Zied Abdullaev; Alexey K Shaytan; Corey A Carter; Anish Thomas; Arun Rajan; Young Song; Stephanie Pitts; Kevin Chen; Sara Bass; Joseph Boland; Ken-Ichi Hanada; Jinqiu Chen; Paul S Meltzer; Anna R Panchenko; James C Yang; Svetlana Pack; Giuseppe Giaccone; David S Schrump; Javed Khan; Udayan Guha
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-11

9.  Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers.

Authors:  E Conde; B Angulo; E Izquierdo; L Paz-Ares; C Belda-Iniesta; M Hidalgo; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

Review 10.  Analysis of different HER-2 mutations in breast cancer progression and drug resistance.

Authors:  Zijia Sun; Yaqin Shi; Yan Shen; Lulu Cao; Wenwen Zhang; Xiaoxiang Guan
Journal:  J Cell Mol Med       Date:  2015-08-25       Impact factor: 5.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.